BiotechTube

INO-4800 + Placebo

Phase 2/3Terminated
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronavirus Infection

Conditions

Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease

Trial Timeline

Nov 30, 2020 → Sep 13, 2022

NCT ID
NCT04642638

About INO-4800 + Placebo

INO-4800 + Placebo is a phase 2/3 stage product being developed by Inovio Pharmaceuticals for Coronavirus Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT04642638. Target conditions include Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04642638Phase 2/3Terminated

Competing Products

20 competing products in Coronavirus Infection

See all competitors
ProductCompanyStageHype Score
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mgEli LillyPhase 2/3
65
EQ001 + EQ001 PlaceboBioconPhase 3
77
Mesenchymal stem cellRohto PharmaceuticalPhase 1
33
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04AbbViePhase 1
33
Ibrutinib + PlaceboAbbViePhase 2
52
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
52
EVUSHELDAstraZenecaPre-clinical
23
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
52
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
33
Molnupiravir + PlaceboMerckPhase 3
77
Molnupiravir + PlaceboMerckPhase 2/3
65
V590MerckPhase 1
33
Molnupiravir + PlaceboMerckPhase 2/3
65
V591MerckPhase 1/2
41
Efprezimod alfa + PlaceboMerckPhase 3
77
M5049 + M5049 + PlaceboMerckPhase 2
52
Molnupiravir + PlaceboMerckPhase 3
77
Frespaciguat + PlaceboMerckPhase 1
33
Canakinumab + PlaceboNovartisPhase 3
77

Other Products from Inovio Pharmaceuticals

VGX-3100 + PlaceboPhase 3
69
VGX-3100 + Matched PlaceboPhase 3
69
INO-3112 vaccine + Cisplatin chemotherapyPhase 2
44
INO-4700 + Placebo + INO-4700Phase 2
44
ChronVac-C + SOC + SOCPhase 2
44